Nothing Special   »   [go: up one dir, main page]

BR112022010934A2 - Métodos para tratar copd administrando um antagonista de il-33 - Google Patents

Métodos para tratar copd administrando um antagonista de il-33

Info

Publication number
BR112022010934A2
BR112022010934A2 BR112022010934A BR112022010934A BR112022010934A2 BR 112022010934 A2 BR112022010934 A2 BR 112022010934A2 BR 112022010934 A BR112022010934 A BR 112022010934A BR 112022010934 A BR112022010934 A BR 112022010934A BR 112022010934 A2 BR112022010934 A2 BR 112022010934A2
Authority
BR
Brazil
Prior art keywords
methods
antagonist
administering
treat copd
copd
Prior art date
Application number
BR112022010934A
Other languages
English (en)
Inventor
Abdulai Raolat
Boddy Alexander
Lou Xiaodong
Dukovic Deborah
Jessel Andreas
Staudinger Heribert
Teper Ariel
Goulaouic Helene
Ruddy Marcella
Amin Nikhil
Harel Sivan
Nivens Chad
Lederer David
Original Assignee
Sanofi Biotechnology
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology, Regeneron Pharma filed Critical Sanofi Biotechnology
Publication of BR112022010934A2 publication Critical patent/BR112022010934A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

MÉTODOS PARA TRATAR COPD ADMINISTRANDO UM ANTAGONISTA DE IL-33. A presente invenção refere-se a métodos para tratar ou prevenir a COPD e condições associadas em um paciente que são fornecidos. Métodos que compreendem a administração a um indivíduo em necessidade dos mesmos de uma composição terapêutica compreendendo um antagonista de interleucina-33 (IL-33), tal como um anticorpo anti-IL-33 ou fragmento de ligação ao antígeno do mesmo, são fornecidos.
BR112022010934A 2019-12-06 2020-12-04 Métodos para tratar copd administrando um antagonista de il-33 BR112022010934A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962944878P 2019-12-06 2019-12-06
US202062964966P 2020-01-23 2020-01-23
US202063082502P 2020-09-24 2020-09-24
PCT/US2020/063404 WO2021113707A1 (en) 2019-12-06 2020-12-04 Methods for treating copd by administering an il-33 antagonist

Publications (1)

Publication Number Publication Date
BR112022010934A2 true BR112022010934A2 (pt) 2022-11-29

Family

ID=74104197

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010934A BR112022010934A2 (pt) 2019-12-06 2020-12-04 Métodos para tratar copd administrando um antagonista de il-33

Country Status (12)

Country Link
US (1) US20210230265A1 (pt)
EP (1) EP4069365A1 (pt)
JP (1) JP2023505215A (pt)
KR (1) KR20220110553A (pt)
CN (1) CN114786775A (pt)
AU (1) AU2020398168A1 (pt)
BR (1) BR112022010934A2 (pt)
CA (1) CA3160521A1 (pt)
IL (1) IL293544A (pt)
MX (1) MX2022006812A (pt)
TW (1) TW202134273A (pt)
WO (1) WO2021113707A1 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
RS52643B (en) 2006-06-02 2013-06-28 Regeneron Pharmaceuticals Inc. HIGH AFINITY ANTIBODIES TO THE HUMAN IL-6 RECEPTOR
KR20160061352A (ko) * 2013-10-15 2016-05-31 메디뮨 엘엘씨 벤랄리주맙을 사용하여 만성 폐쇄성 폐 질환을 치료하는 방법
TWI784988B (zh) * 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法

Also Published As

Publication number Publication date
IL293544A (en) 2022-08-01
AU2020398168A1 (en) 2022-07-28
US20210230265A1 (en) 2021-07-29
KR20220110553A (ko) 2022-08-08
MX2022006812A (es) 2022-08-25
JP2023505215A (ja) 2023-02-08
CA3160521A1 (en) 2021-06-10
WO2021113707A1 (en) 2021-06-10
EP4069365A1 (en) 2022-10-12
TW202134273A (zh) 2021-09-16
CN114786775A (zh) 2022-07-22

Similar Documents

Publication Publication Date Title
PH12017501934A1 (en) Methods for treating or preventing migraine headache
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
PH12018500642A1 (en) Anti-garp antibody
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
EA201791675A1 (ru) Человеческие антитела к гликопротеину вируса эбола
MX2019002510A (es) Metodos para usar un anticuerpo biespecifico que reconoce el factor de coagulacion ix y/o el factor de coagulacion ix activado y el factor de coagulacion x y/o factor de coagulacion x activado.
BR112022002442A2 (pt) Terapias de imuno-oncologia com conjugados de il-2
BR112020016331A8 (pt) Métodos para tratar câncer com anticorpos anti-pd-1
BR112020015915A8 (pt) Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
EA201891388A1 (ru) Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека
BR112016026560A2 (pt) Método para tratar uma complicação de uma doença hepática crônica, método para tratar hipertensão portal, método para inibir uma cascata de sinalização de tnf-a e de a-fas; composição farmacêutica, kit, método de tratamento, método para tratar uma afecção
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
BR112019022280A2 (pt) tratamento de cânceres de her2 positivo
EA201891853A1 (ru) Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112021014699A2 (pt) Métodos de tratamento de mieloma múltiplo
NZ629828A (en) Methods for the treatment of b cell-mediated inflammatory diseases
EA201891514A1 (ru) Комбинированная терапия ингибитором бромодомена и экстратерминального белка
BR112021021195A2 (pt) Métodos para tratamento ou prevenção da asma pela administração de um antagonista de il-33
BR112019011350A2 (pt) terapia de combinação
BR112023026111A2 (pt) Anticorpo anti-cd40, fragmento de ligação ao antígeno e uso médico do mesmo
BR112016023011A2 (pt) tratamento de câncer gástrico
BR112016008082A2 (pt) métodos para tratamento de doença pulmonar obstrutiva crônica usando benralizumab